No significant difference in all-day hypoglycemia between treatments was found, which corresponds to the findings of the HypoDeg trial (Heller et al., 2012; Pedersen-Bjergaard et al., 2022) but differs from the SWITCH-1 trial, where an 11% lower risk of all-day hypoglycemia was found during treatment with insulin degludec (Table 5) (Lane et al., 2017). Here, INS is linked to Hypoglycemia.